



Meeting with Centre for Drug Evaluation of NMPA of China

September 9, 2019, Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd. had a very successful meeting with the reviewers from the Center for Drug Evaluation of NMPA of China. The purpose of the meeting was to discuss the planned combination trial of the new drugs, anti-PD-L1 monoclonal antibody and Oncolytic virus Pexa-vec. During the meeting, reviewers gave positive feedback and clear guidance to Zhaoke's request and trial protocol. After discussion, reviewers agreed that Zhaoke can initiate the related combination trial and should submit the IND application as soon as possible.

Contact Person: Vivian Fung

+852 2314 1282 or info@leespharm.com